Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating reiterated by stock analysts at Stifel Nicolaus in a note issued to investors on Tuesday, October 24th. They currently have a $65.00 price objective on the stock. Stifel Nicolaus’ price target would indicate a potential downside of 5.97% from the company’s current price.
Other research analysts have also issued research reports about the stock. Cantor Fitzgerald restated a “buy” rating and issued a $75.00 price target on shares of Zoetis in a research report on Wednesday, September 6th. Piper Jaffray Companies set a $73.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, August 25th. Cowen and Company set a $70.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Thursday, August 24th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a research note on Monday, July 17th. Finally, BidaskClub lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 20th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $67.06.
Zoetis (ZTS) opened at $69.13 on Tuesday. Zoetis has a 12 month low of $48.24 and a 12 month high of $70.48. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The company has a market cap of $33,769.08, a P/E ratio of 31.79, a P/E/G ratio of 2.03 and a beta of 1.02.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter last year, the business earned $0.52 earnings per share. research analysts expect that Zoetis will post 2.36 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/12/zoetis-inc-zts-earns-buy-rating-from-stifel-nicolaus.html.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sii Investments Inc. WI raised its holdings in Zoetis by 0.3% in the 1st quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock worth $383,000 after acquiring an additional 23 shares during the period. Ironwood Investment Management LLC raised its holdings in Zoetis by 0.7% in the 2nd quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock worth $429,000 after acquiring an additional 48 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in Zoetis by 1.3% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after acquiring an additional 55 shares during the period. Wilbanks Smith & Thomas Asset Management LLC raised its holdings in Zoetis by 1.8% in the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock worth $354,000 after acquiring an additional 98 shares during the period. Finally, First Manhattan Co. raised its holdings in Zoetis by 1.1% in the 2nd quarter. First Manhattan Co. now owns 9,099 shares of the company’s stock worth $567,000 after acquiring an additional 99 shares during the period. Hedge funds and other institutional investors own 92.90% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.